No need for 60%-plus discounts on Repatha, Amgen says, rolling out real-world data as backup
admin 23rd August 2017 Uncategorised 0Amgen has rolled out a new economic analysis of Repatha’s outcomes study, Fourier, which initially failed to wow the market when unveiled earlier this year. The gist? The PCSK9 drug is cost-effective at $9,669 per year or less, almost $5,000 off its list price.
More: No need for 60%-plus discounts on Repatha, Amgen says, rolling out real-world data as backup
Source: fierce